|
AU2003223601A1
(en)
|
2002-04-12 |
2003-10-27 |
King's College London |
ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4
|
|
JP2006502978A
(ja)
|
2002-06-17 |
2006-01-26 |
ワイス |
ブチロフィリン４またはｂ７−ｌ１によるｔ細胞活性化阻害
|
|
EP1702622A1
(en)
|
2005-03-18 |
2006-09-20 |
CONARIS research institute AG |
Soluble BTNL2 protein useful to inhibit inflammatory disorders
|
|
WO2007110205A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
WO2008154516A2
(en)
|
2007-06-11 |
2008-12-18 |
The Board Of Regents, The Universtity Ot Texas System |
Btnl2 fusion protein for t-cell activity modulation
|
|
GB0717101D0
(en)
|
2007-09-03 |
2007-10-10 |
Cambridge Entpr Ltd |
Tumour marker
|
|
EP3663318A1
(en)
*
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
AU2011237365B2
(en)
|
2010-04-09 |
2015-01-29 |
Amgen Inc. |
BTNL9 proteins, nucleic acids, and antibodies and uses thereof
|
|
CA2796633C
(en)
*
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
DK2771364T3
(da)
*
|
2011-10-27 |
2019-08-19 |
Genmab As |
Fremstilling af heterodimere proteiner
|
|
US10131709B2
(en)
|
2011-12-28 |
2018-11-20 |
Immunoqure Ag |
Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
|
|
EP2797952B1
(en)
|
2011-12-28 |
2019-02-27 |
ImmunoQure AG |
Method of providing monoclonal auto-antibodies with desired specificity
|
|
AU2013292510A1
(en)
|
2012-07-19 |
2015-02-05 |
Amgen Inc. |
Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
|
|
AU2013371826A1
(en)
|
2013-01-01 |
2015-08-13 |
Kahr Medical Ltd. |
Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
|
|
GB201300052D0
(en)
|
2013-01-03 |
2013-02-20 |
Transimmune Ag |
Method for obtaining immuno-suppressive dendritic cells
|
|
GB201300049D0
(en)
|
2013-01-03 |
2013-02-20 |
Transimmune Ag |
Method for obtaining immuno-stimulatory dendritic cells
|
|
US10112995B2
(en)
|
2013-07-03 |
2018-10-30 |
Immunoqure Ag |
Human anti-IFN-α antibodies
|
|
WO2015001047A1
(en)
|
2013-07-03 |
2015-01-08 |
Immunoqure Ag |
Method of providing anti-human cytokine antibodies for pharmaceutical use
|
|
CA2916895C
(en)
|
2013-07-03 |
2022-08-09 |
Immunoqure Ag |
Human anti-il-32 antibodies
|
|
AU2014354587A1
(en)
|
2013-11-29 |
2016-06-02 |
Csl Limited |
Method of treating cancer
|
|
US10501540B2
(en)
|
2014-04-10 |
2019-12-10 |
Lava Therapeutics B.V. |
Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
|
|
GB201413665D0
(en)
|
2014-07-03 |
2014-09-17 |
Transimmune Ag And Yale University |
Method for obtaining globally activated monocytes
|
|
EP3223849A4
(en)
|
2014-11-25 |
2018-05-30 |
Albert Einstein College of Medicine, Inc. |
Btnl9 and ermap as novel inhibitors of the immune system for immunotherapies
|
|
EP3173092B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
|
WO2016191305A1
(en)
*
|
2015-05-22 |
2016-12-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Btn3a ectodomain proteins and methods of use
|
|
BR112018006578A2
(pt)
|
2015-10-01 |
2018-12-26 |
Heat Biologics, Inc. |
composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
|
|
CA3003077A1
(en)
|
2015-10-30 |
2017-05-04 |
King's College London |
Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells
|
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
|
GB201521389D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
CN116769054A
(zh)
*
|
2016-02-05 |
2023-09-19 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
|
KR20180130541A
(ko)
|
2016-03-29 |
2018-12-07 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
|
|
US11634493B2
(en)
*
|
2016-11-02 |
2023-04-25 |
Beijing Proteome Research Center |
Tumor immunotherapy target and application thereof
|
|
WO2018201130A1
(en)
|
2017-04-28 |
2018-11-01 |
The Brigham And Women's Hospital, Inc. |
Targeting gamma-delta t cells in obesity and cachexia
|
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
KR20250036941A
(ko)
|
2017-05-31 |
2025-03-14 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
|
EP3635007A1
(en)
|
2017-06-06 |
2020-04-15 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
US20200297871A1
(en)
|
2017-09-15 |
2020-09-24 |
King's College London |
Compositions and methods for enhancing gamma delta t cells in the gut
|
|
AU2018335955B2
(en)
|
2017-09-21 |
2024-12-12 |
Centre National De La Recherche Scientifique - Cnrs - |
Antibodies having specificity for BTN2 and uses thereof
|
|
US11098093B2
(en)
*
|
2019-01-07 |
2021-08-24 |
Shattuck Labs, Inc. |
Heterodimeric proteins for modulating gamma delta T cells
|